Novartis's 'near miss' in Q2 driven by out-going business
This article was originally published in Scrip
Executive Summary
Novartis reported second quarter sales of $14.64bn, up 2% but slightly lower than consensus forecasts. The miss was driven by the soon to be divested Vaccines and Consumer units, "Core divisional performance was in-line with expectations," note Deutsche Bank analysts.